🇺🇸 lipid-lowering treatment in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Abdominal Pain Upper — 1 report (10%)
  2. Angina Pectoris — 1 report (10%)
  3. Death — 1 report (10%)
  4. Dizziness — 1 report (10%)
  5. Dyspnoea — 1 report (10%)
  6. Erythema — 1 report (10%)
  7. Haemorrhage — 1 report (10%)
  8. Myocardial Infarction — 1 report (10%)
  9. Renal Haemorrhage — 1 report (10%)
  10. Thrombocytopenia — 1 report (10%)

Source database →

lipid-lowering treatment in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is lipid-lowering treatment approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for lipid-lowering treatment in United States?

Kumamoto University is the originator. The local marketing authorisation holder may differ — check the official source linked above.